1-20 of 20
Tim Heise
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Tim Heise, J. Hans DeVries, Shweta Urva, Jing Li, Edward J. Pratt, Melissa K. Thomas, Kieren J. Mather, Chrisanthi A. Karanikas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Journal: Diabetes Care
Diabetes Care 2023;46(5):998–1004
https://doi.org/10.2337/dc22-1710
Published: 01 March 2023
View article titled, Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Open the PDF for Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes in another window
Journal Articles

Sustained Intensive Treatment and Long-term Effects on HbA1c Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI

Marcus Lind, Arndís F. Ólafsdóttir, Irl B. Hirsch, Jan Bolinder, Sofia Dahlqvist, Aldina Pivodic, Jarl Hellman, Magnus Wijkman, Erik Schwarcz, Henrik Albrektsson, Tim Heise, William Polonsky
Journal: Diabetes Care
Diabetes Care 2021;44(1):141–149
https://doi.org/10.2337/dc20-1468
Published: 16 November 2020
View article titled, Sustained Intensive Treatment and Long-term Effects on HbA<sub>1c</sub> Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI
Open the PDF for Sustained Intensive Treatment and Long-term Effects on HbA<sub>1c</sub> Reduction (SILVER Study) by CGM in People With Type 1 Diabetes Treated With MDI in another window
Journal Articles

Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis

Max L. Eckstein, Juliano Boufleur Farinha, Olivia McCarthy, Daniel J. West, Jane E. Yardley, Lia Bally, Thomas Zueger, Christoph Stettler, Winston Boff, Alvaro Reischak-Oliveira, Michael C. Riddell, Dessi P. Zaharieva, Thomas R. Pieber, Alexander Müller, Philipp Birnbaumer, Faisal Aziz, Laura Brugnara, Hanne Haahr, Eric Zijlstra, Tim Heise, Harald Sourij, Michael Roden, Peter Hofmann, Richard M. Bracken, Dominik Pesta, Othmar Moser
Journal: Diabetes Care
Diabetes Care 2021;44(1):240–247
https://doi.org/10.2337/dc20-1496
Published: 12 November 2020
View article titled, Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis
Open the PDF for Differences in Physiological Responses to Cardiopulmonary Exercise Testing in Adults With and Without Type 1 Diabetes: A Pooled Analysis in another window
Journal Articles

The Association Between HbA1c and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)

Shilan Seyed Ahmadi, Klara Westman, Aldina Pivodic, Arndís F. Ólafsdóttir, Sofia Dahlqvist, Irl B. Hirsch, Jarl Hellman, Magnus Ekelund, Tim Heise, William Polonsky, Magnus Wijkman, Erik Schwarcz, Marcus Lind
Journal: Diabetes Care
Diabetes Care 2020;43(9):2017–2024
https://doi.org/10.2337/dc19-2606
Published: 08 July 2020
View article titled, The Association Between HbA<sub>1c</sub> and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4)
Open the PDF for The Association Between HbA<sub>1c</sub> and Time in Hypoglycemia During CGM and Self-Monitoring of Blood Glucose in People With Type 1 Diabetes and Multiple Daily Insulin Injections: A Randomized Clinical Trial (GOLD-4) in another window
Journal Articles

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen, Francesca Macchi, Daniela Lamers, Birgit Kronshage, Daniél Vega Møller, Tim Heise
Journal: Diabetes Care
Diabetes Care 2018;41(3):531–537
https://doi.org/10.2337/dc17-1402
Published: 22 December 2017
View article titled, Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
Open the PDF for Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog in another window
Includes: Supplementary data
Journal Articles

Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control

Susanne Famulla, Ulrike Hövelmann, Annelie Fischer, Hans-Veit Coester, Lidia Hermanski, Matthias Kaltheuner, Lars Kaltheuner, Lutz Heinemann, Tim Heise, Laurence Hirsch
Journal: Diabetes Care
Diabetes Care 2016;39(9):1486–1492
https://doi.org/10.2337/dc16-0610
Published: 13 July 2016
View article titled, Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control
Open the PDF for Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control in another window
Includes: Supplementary data
Journal Articles

New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

Reinhard H.A. Becker, Raphael Dahmen, Karin Bergmann, Anne Lehmann, Thomas Jax, Tim Heise
Journal: Diabetes Care
Diabetes Care 2015;38(4):637–643
https://doi.org/10.2337/dc14-0006
Published: 22 August 2014
View article titled, New Insulin Glargine 300 Units·mL<sup>−1</sup> Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL<sup>−1</sup>
Open the PDF for New Insulin Glargine 300 Units·mL<sup>−1</sup> Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL<sup>−1</sup> in another window
Includes: Supplementary data
Journal Articles

Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

Geremia B. Bolli, MD, Annke D. Hahn, PHD, Ronald Schmidt, PHD, Tanja Eisenblaetter, PHD, Raphael Dahmen, MD, Tim Heise, MD, Reinhard H.A. Becker, MD
Journal: Diabetes Care
Diabetes Care 2012;35(12):2626–2630
https://doi.org/10.2337/dc12-0270
Published: 14 November 2012
View article titled, Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes
Open the PDF for Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes in another window
Includes: Supplementary data
Journal Articles

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial

Tim Heise, MD, Cees J. Tack, MD, Robert Cuddihy, MD, Jaime Davidson, MD, Didier Gouet, MD, Andreas Liebl, MD, Enrique Romero, MD, Henriette Mersebach, MD, Patrik Dykiel, MSC, Rolf Jorde, MD
Journal: Diabetes Care
Diabetes Care 2011;34(3):669–674
https://doi.org/10.2337/dc10-1905
Published: 17 February 2011
View article titled, A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: <subtitle>A randomized, controlled trial</subtitle>
Open the PDF for A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: <subtitle>A randomized, controlled trial</subtitle> in another window
Includes: Supplementary data
Journal Articles

Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes

Christoph Kapitza, MD, Eric Zijlstra, PHD, Lutz Heinemann, PHD, M. Cristina Castelli, PHD, Gary Riley, DVM, PHD, Tim Heise, MD
Journal: Diabetes Care
Diabetes Care 2010;33(6):1288–1290
https://doi.org/10.2337/dc09-1807
Published: 25 February 2010
View article titled, Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes
Open the PDF for Oral Insulin: A Comparison With Subcutaneous Regular Human Insulin in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy

Tim Heise, MD, Lutz Heinemann, PHD, Ulrike Hövelmann, MD, Bianca Brauns, ARZT, Leszek Nosek, MD, Hanne L. Haahr, PHD, Klaus J. Olsen, PHD
Journal: Diabetes Care
Diabetes Care 2009;32(8):1431–1433
https://doi.org/10.2337/dc09-0097
Published: 01 June 2009
View article titled, Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy
Open the PDF for Biphasic Insulin Aspart 30/70: Pharmacokinetics and Pharmacodynamics Compared With Once-Daily Biphasic Human Insulin and Basal-Bolus Therapy in another window
Journal Articles

Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects With Type 2 Diabetes

Klaus Rave, MD, Tim Heise, MD, Andreas Pfützner, MD, PHD, Anders H. Boss, MD, MFPM
Journal: Diabetes Care
Diabetes Care 2007;30(9):2307–2308
https://doi.org/10.2337/dc07-0478
Published: 01 September 2007
View article titled, Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects With Type 2 Diabetes
Open the PDF for Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects With Type 2 Diabetes in another window
Journal Articles

The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: Response to Chantelau et al.

Tim Heise, MD, Susanne Bott, MD, Corinna Tusek, MD, Jens-Armin Stephan, MD, Tom Kawabata, PHD, Deborah Finco-Kent, MS, Cameron Liu, PHD, Alan Krasner, MD
Journal: Diabetes Care
Diabetes Care 2006;29(2):477–478
https://doi.org/10.2337/diacare.29.02.06.dc05-2187
Published: 01 February 2006
View article titled, The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: <subtitle>Response to Chantelau et al.</subtitle>
Open the PDF for The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: <subtitle>Response to Chantelau et al.</subtitle> in another window
Journal Articles

The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: A prospective randomized pharmacodynamic study

Tim Heise, MD, Susanne Bott, MD, Corinna Tusek, MD, Jens-Armin Stephan, MD, Tom Kawabata, PHD, Deborah Finco-Kent, MS, Cameron Liu, PHD, Alan Krasner, MD
Journal: Diabetes Care
Diabetes Care 2005;28(9):2161–2169
https://doi.org/10.2337/diacare.28.9.2161
Published: 01 September 2005
View article titled, The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: <subtitle>A prospective randomized pharmacodynamic study</subtitle>
Open the PDF for The Effect of Insulin Antibodies on the Metabolic Action of Inhaled and Subcutaneous Insulin: <subtitle>A prospective randomized pharmacodynamic study</subtitle> in another window
Journal Articles

Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes

Thomas Danne, MD, Reinhard H. A. Becker, MD, Tim Heise, MD, Claudia Bittner, MD, Annke D. Frick, PHD, Klaus Rave, MD
Journal: Diabetes Care
Diabetes Care 2005;28(9):2100–2105
https://doi.org/10.2337/diacare.28.9.2100
Published: 01 September 2005
View article titled, Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes
Open the PDF for Pharmacokinetics, Prandial Glucose Control, and Safety of Insulin Glulisine in Children and Adolescents With Type 1 Diabetes in another window
Journal Articles

Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin

Klaus Rave, MD, Susanne Bott, MD, Lutz Heinemann, PHD, Sue Sha, MD, PHD, Reinhard H.A. Becker, MD, PHD, Susan A. Willavize, PHD, Tim Heise, MD
Journal: Diabetes Care
Diabetes Care 2005;28(5):1077–1082
https://doi.org/10.2337/diacare.28.5.1077
Published: 01 May 2005
View article titled, Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin
Open the PDF for Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin in another window
Journal Articles

Absorption and Metabolic Effect of Inhaled Insulin: Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes

Ayesh D. Perera, PHD, Christoph Kapitza, MD, Leszek Nosek, MD, Robert S. Fishman, MD, David A. Shapiro, MD, Tim Heise, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 2002;25(12):2276–2281
https://doi.org/10.2337/diacare.25.12.2276
Published: 01 December 2002
View article titled, Absorption and Metabolic Effect of Inhaled Insulin: <subtitle>Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes</subtitle>
Open the PDF for Absorption and Metabolic Effect of Inhaled Insulin: <subtitle>Intrapatient variability after inhalation via the Aerodose Insulin Inhaler in patients with type 2 diabetes</subtitle> in another window
Journal Articles

Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients

Klaus Rave, Tim Heise, Andreas Pfützner, Lutz Heinemann, Peter T. Sawicki
Journal: Diabetes Care
Diabetes Care 2001;24(5):886–890
https://doi.org/10.2337/diacare.24.5.886
Published: 01 May 2001
View article titled, Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients
Open the PDF for Impact of Diabetic Nephropathy on Pharmacodynamic and Pharmacokinetic Properties of Insulin in Type 1 Diabetic Patients in another window
Journal Articles

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

Tim Heise, MD, Christian Weyer, MD, Andreas Serwas, MD, Sebastian Heinrichs, MD, Johannes Osinga, MD, Paris Roach, MD, Jim Woodworth, PHD, Uwe Gudat, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 1998;21(5):800–803
https://doi.org/10.2337/diacare.21.5.800
Published: 01 May 1998
View article titled, Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin
Open the PDF for Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin in another window
Journal Articles

Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture

Christian Weyer, MD, Tim Heise, MD, Lutz Heinemann, PHD
Journal: Diabetes Care
Diabetes Care 1997;20(10):1612–1614
https://doi.org/10.2337/diacare.20.10.1612
Published: 01 October 1997
View article titled, Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture
Open the PDF for Insulin Aspart in a 30/70 Premixed Formulation: Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture in another window